Citations

Clear

2476 citation(s) found for "MD, Miller".

Canine-Associated Capnocytophaga canimorsus Bacteremia in an Older Adult Without Classical Immunosuppressive Risk Factors
Hirte, Ingrid L. , McHugh, Jack W., McHugh, Jack , Miller, Nathaniel E , Hirte, Ingrid L. , McHugh, Jack , Miller, Nathaniel E.

Mayo Clinic

American Journal of Case Reports | July 6, 2026 | Volume: 27 | Issue: No issue available | Pages: No page available

10.12659/ajcr.952980 | PMID 42640881 Get It

Vaccine Therapy for the Management of Penile Cancer: Evidence, Opportunities and Challenges
Hatoum, Firas , Nehme, Ricardo , Fazili, Adnan, Miller, Justin, Johnson, Jeffrey S., Le, Casey, Spiess, Philippe E. , Chahoud, Jad , Spiess, Philippe E , Fazili, Adnan , Johnson, J. Hallanger

Mayo Clinic

Vaccines | July 6, 2026 | Volume: 14 | Issue: 7 | Pages: 597

10.3390/vaccines14070597 | PMID 42506634 Get It

Penile squamous cell carcinoma (PSCC) is a rare malignancy with limited therapeutic options in advanced and recurrent diseases. Advanced PSCC is typically managed with multimodal therapy, including neoadjuvant chemotherapy or chemoradiation followed by surgery; however, durable responses remain uncommon, and outcomes after recurrence are poor. Cancer vaccines represent a promising immunotherapeutic strategy, as these treatments induce tumor-specific immunity and heightened immune surveillance against penile cancer cells. While therapeutic cancer vaccines have not yet demonstrated consistent clinical efficacy as monotherapy in PSCC, their integration with complementary immune-modulating approaches, particularly immune checkpoint blockade, represents a rational strategy to enhance antitumor immunity. This review summarizes the rationale for vaccine development in PSCC, with emphasis on HPV-derived antigens, neoantigens, and emerging tumor-associated targets. We examine major vaccine platforms, including viral-vector, peptide-based, nucleic acid, and dendritic cell-based approaches. We also discuss how spatial transcriptomics, single-cell RNA sequencing, artificial intelligence-assisted antigen prediction, and nanotechnology-enhanced delivery systems may support future personalized vaccine development. Overall, therapeutic vaccines remain investigational in PSCC but may become relevant within biomarker-driven, combination-based immunotherapy strategies.
Automated AI-Based Aortic Measurements From Attenuation Correction CT as an Adjunctive Cardiovascular Risk Biomarker: An International Multicenter Study
Marcinkiewicz, Anna M , Shanbhag, Aakash , Chareonthaitawee, Panithaya , Zhang, Wenhao, Jilaihawi, Hasan , Zaid, Ryan , Cadet, Sebastien , Ramirez, Giselle , Lemley, Mark , Yi, Jirong , Hijazi, Waseem , Liang, Joanna X. , Fehér, Attila , Mason, Steve, Alexanderson, Erick, Carvajal-Juarez, Isabel , Travin, Mark I. , Rosamond, Thomas, Wopperer, Samuel , Berman, Daniel S. , Carli, Marcelo F. Di , Al-Jilaihawi, Hasanian , Builoff, Valerie , Calsavara, Vinicius F , Einstein, Andrew Jeffrey , Miller, Edward J , Feher, Attila , Ruddy, Terrence D , Le, Viet T , Knight, Stacey , Carvajal-Juarez, Isabel , Slipczuk, Leandro , Rosamond, Thomas L , Wopperer, Samuel , Berman, Daniel , Dey, Damini , Di Carli, Marcelo F , Miller, Robert J H , Slomka, Piotr J , Chareonthaitawee, Panithaya , Lemley, Mark , Ramirez, Giselle , Shanbhag, Aakash , Zaid, Ryan , Miller, Edward J. , Le, Viet T. , Mason, Steve, Knight, Stacey , Alexanderson, Erick , Slipczuk, Leandro , Dey, Damini , Miller, Robert J.H.

Mayo Clinic

Circulation: Cardiovascular Imaging | July 2, 2026 | Volume: 19 | Issue: 7 | Pages: No page available

10.1161/circimaging.125.019726 | PMID 42389791 Get It

BACKGROUND: Aortic enlargement is a powerful predictor of dissection and rupture, yet it is rarely evaluated during routine myocardial perfusion imaging, despite the widespread availability of computed tomography (CT) attenuation correction scans. The aim of this study was to determine whether fully automated, opportunistically derived, artificial intelligence-based aortic measurements from myocardial perfusion imaging CT attenuation correction scans are associated with adverse outcomes in a large multicenter cohort. METHODS: CT attenuation correction scans from patients undergoing positron emission tomography/CT and single-photon emission CT/CT myocardial perfusion imaging across 10 centers were included. A deep learning model automatically segmented the thoracic aorta, and a postprocessing algorithm extracted maximum ascending and descending diameters. The aortic size index was calculated by indexing the diameter to body surface area. RESULTS: A total of 29 339 patients (56% men; median age, 66 years [interquartile range, 58–75 years]) were included. Over a median follow-up of 3.5 years (interquartile range, 1.9–5.0 years), 5083 (17.3%) patients died. Median ascending and descending aortic size index values were 1.8 cm/m 2 (interquartile range, 1.6–2.0) and 1.5 cm/m 2 (interquartile range, 1.4–1.6), respectively, with an increase with age and higher values in females. Elevated aortic size index thresholds (ascending >2.2 cm/m 2 ; descending >1.6 cm/m 2 ) were significantly associated with increased all-cause mortality (ascending: adjusted hazard ratio, 1.16 [95% CI, 1.07–1.26], P <0.001; descending: adjusted hazard ratio, 1.23 [95% CI, 1.14–1.31]; P <0.001). Notably, the prognostic value of an abnormal aortic size index persisted independent of age, sex, and perfusion abnormalities. CONCLUSIONS: Artificial intelligence can unlock previously unused information within routine myocardial perfusion imaging CT attenuation correction scans by rapidly and automatically quantifying aortic size at scale. Opportunistic aortic measurements derived from CT attenuation correction may serve as an adjunctive risk biomarker and could add prognostic value to standard myocardial perfusion imaging without additional imaging or radiation.
Neonatal Survival After Serial Amnioinfusions for Anhydramnios Due to Fetal Kidney Failure
Baschat, Ahmet A., Johnson, Anthony , Blumenfeld, Yair J., Schenone, Mauro H., Gebb, Juliana , Moldenhauer, Julie S., Zaretsky, Michael V. , Chmait, Ramen H., Gonzalez, Juan M., Rl, Miller, Krispin, Eyal , Shamshirsaz, A H A, Bligard, Katherine H. , Kalan, Amanda, Cortes, Magdalena Sanz, Bendel-Stenzel, Ellen, Menon, Shina , Wong, Cynthia, Kwak, Cecilia, Gallup, J Y, McKenna, Kristin, Marron, L, Tran, Cheryl L. , Behrendt, Nicholas, Galan, Henry L. , Samuels, Joshua, Swinford, Rita, Rosner, Mara, Kush, Michelle L, Nasr, Isam, Vasu, Samhita , Boss, Renee D. , Jelin, Angie C., Thompson, Richard E. , Davis, Jonathan M. , Warren, Daniel , Atkinson, Meredith A. , Gebb, Juliana S , Menon, Shina , Miller, Jena L. , Baschat, Ahmet , Blumenfeld, Yair J. , Schenone, Mauro H , Moldenhauer, Julie S. , Chmait, Ramen H. , Gonzalez, Juan, Cortes, Magdalena Sanz , Moon‐Grady, Anita J. , Bendel‐Stenzel, Ellen , Grimm, Paul, Marron, Leah, Hanna, Christian , Swinford, Rita D., Keiser, Amaris , Rosner, Mara , Nasr, Isam W. , Boss, Renee Denise , Jelin, Angie Child , Hanley, Daniel F.

Mayo Clinic

JAMA | July 1, 2026 | Volume: 336 | Issue: 6 | Pages: 473

10.1001/jama.2026.8568 | PMID 42384373 Get It

Importance Anhydramnios from fetal kidney failure causes lethal pulmonary hypoplasia. Serial amnioinfusions have shown promise in mitigating pulmonary disease from bilateral renal agenesis, but efficacy and safety for other causes of fetal kidney failure are unproven. Objective To assess the efficacy of serial amnioinfusions initiated before 26 weeks’ gestation to mitigate lethal pulmonary hypoplasia in cases of anhydramnios due to fetal kidney failure. Design, Setting, and Participants Prospective, nonrandomized clinical trial conducted at 13 US fetal therapy centers from December 2018 to February 2025. Outcomes for maternal-fetal pairs with anhydramnios before 22 weeks’ gestation due to fetal kidney failure without bilateral renal agenesis are reported; data collection for surviving infants continued until February 13, 2026. Exposure Thirty-two participants underwent serial amnioinfusions with isotonic fluid beginning before 26 weeks’ gestation. Main Outcomes and Measures The primary end point was neonatal survival for 14 days or longer with dialysis access placement. Secondary outcome measures of survival to discharge home and kidney transplant are reported. Results Twenty-nine of 32 participants (91%) had a live birth, with a median (IQR) gestational age at delivery of 34 weeks 1 day (31 weeks 5 days to 34 weeks 6 days). All participants delivered before 37 weeks’ gestation. No unexpected serious maternal adverse events occurred, and the most common maternal complications were preterm prelabor rupture of membranes in 19 participants (56%) and chorioamniotic separation in 10 (29%). The primary outcome occurred in 19 (65.5%) of 29 live-born neonates (95% CI, 45.7%-82.1%). Factors associated with survival to the primary outcome included receiving more amnioinfusions (median [IQR], 14 [9-18] in survivors vs 7 [4-11] in nonsurvivors; P = .01), longer time interval from first amnioinfusion to preterm prelabor rupture of membranes (63.5 [60.5-74.5] days in survivors vs 29.0 [22.0-56.0] days in nonsurvivors; P = .01), gestational age greater than 32 weeks (79% of survivors vs 38% of nonsurvivors; P = .03), and higher birth weight (2029 [1770-2250] g in survivors vs 1635 [1185-1915] g in nonsurvivors; P = .01). Fourteen live-born infants (48%) survived to hospital discharge at a median (IQR) age of 4.7 (3.4-5.7) months. Of the 11 infants surviving to date, 7 (64%) have undergone kidney transplant between ages 2 years to 5 years. Conclusions and Relevance Serial amnioinfusions mitigated lethal pulmonary hypoplasia in neonates with anhydramnios due to fetal kidney failure. Significant neonatal morbidity and mortality independent of early lung function was noted. Factors associated with survival were consistent with the Renal Anhydramnios Fetal Therapy trial’s bilateral renal agenesis cohort, suggesting common mechanistic pathways for mitigating pulmonary hypoplasia. Trial Registration ClinicalTrials.gov Identifier: NCT03101891
Tobacco smoking disrupts bile acid and tryptophan metabolism in multiple sclerosis
Briggs, Farren , Litwiler, Jevin, Montini, Federico , Esfahani, Mahdis, Sagen, Jessica, Nelson, Flavia, Gregory, Simon, Brambilla, Roberta, Bailey, Jessica N Cooke, Schwerdtfeger, Luke , Cox, Laura, Weiner, Howard, Briggs, Farren Bs , McCauley, Jacob L , Tobin, W Oliver , Schwerdtfeger, Luke A , McCauley, Jacob L. , Trapl, Erika , Bailey, Jessica N. Cooke, Cox, Laura M. , Weiner, Howard , Tobin, W. Oliver

Mayo Clinic

Multiple Sclerosis Journal | July 1, 2026 | Volume: 32 | Issue: 9 | Pages: 972-984

10.1177/13524585261454207 | PMID 42383698 Get It

Background: Smokers with multiple sclerosis (MS) experience worse disease, yet underlying mechanisms remain unknown. Smoking disrupts bile acid and tryptophan metabolism in non-MS populations; both pathways involve host–microbiome co-metabolism and have been linked to MS. Objective: Determine whether smoking perturbs these metabolic pathways in MS and whether such alterations statistically mediate smoking’s effect on MS severity. Methods: We analyzed serum bile acid, tryptophan, and tobacco-related metabolites across four independent MS cohorts ( N = 266) using discovery-replication analyses. Mixed-effects regression assessed replicating associations with current smoking and nicotine exposure. Mediation analyses tested if replicating metabolites were potential mediators between smoking and MS severity. Hypothesis-generating metagenomic analyses explored smoking-associated gut–microbial shifts and metabolite correlations. Results: Current smokers and nicotine-exposed MS subjects had reductions in bile acids and tryptophan metabolites, notably indolepropionate, a neuroprotective, anti-inflammatory gut–microbial metabolite. Lower indolepropionate statistically mediated ~20% of smoking’s adverse effect on MS severity. Metagenomic analyses identified potential smoking-enriched MS-linked taxa, and that indolepropionate broadly co-occurs with microbial networks (e.g. Lachnoclostridium appeared inversely associated with indolepropionate in smokers with MS). Conclusion: Tobacco exposure disrupts host–microbiome tryptophan and bile acid metabolism in persons with multiple sclerosis, with indolepropionate depletion partially mediating disease severity, highlighting a potential mechanistic pathway warranting further investigation in MS smokers.
FTLD‐TDP versus LATE‐NC: Experience of a Brain Bank specializing in FTLD‐TDP
Fischer, D. Luke , Spina, S, Grinberg, Lea T. , Grinberg, Lea , Miller, Bruce L. , Seeley, William W.

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | July 1, 2026 | Volume: 18 | Issue: 3 | Pages: No page available

10.1002/dad2.70411 | PMID 42388895 Get It

Abstract INTRODUCTION Similarities between frontotemporal lobar degeneration with transactive response DNA‐binding protein of 43 kDa (TDP‐43) (FTLD‐TDP) and limbic‐predominant age‐related TDP‐43 encephalopathy neuropathologic change (LATE‐NC) raise questions about whether they represent distinct entities or a single disease spectrum. The literature mostly examined series with disproportionate numbers of LATE‐NC over FTLD‐TDP. METHODS Leveraging a clinicopathological collection of FTLD‐TDP ( N = 148) from the University of California, San Francisco, we compared demographic, clinical, genetic, and neuropathological features of FTLD‐TDP, particularly FTLD‐TDP type A ( N = 39), and LATE‐NC ( N = 42). RESULTS FTLD‐TDP type A cases were younger at onset and death, had shorter disease duration, and frequent genetic causes ( GRN , C9ORF72 ) compared to LATE‐NC, which were mostly sporadic and older. Blinded evaluation of middle frontal gyrus (MFG) TDP‐43 immunostaining alone proved insufficient to reliably differentiate FTLD‐TDP type A from LATE‐NC stage 3. However, factoring in all neuropathologic features, FTLD type A and LATE‐NC could be differentiated with >95% confidence. DISCUSSION These overall findings support distinct diagnostic entities for FTLD‐TDP and LATE‐NC.
Hands-on Education to Increase Comfort and Knowledge Utilizing In-Check TM Inhaler Training Device in Medical Trainees
Strother, Robert K. , Miller, Nathaniel E. , Umbreit, Audrey , Lee, Maddie, Smoak, Julia, Firkus, Danielle , Davis, Amanda, Strother, Robert , Miller, Nathaniel E

Mayo Clinic

Journal of Primary Care & Community Health | June 25, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/21501319261463360 | PMID 42349020 Get It

Introduction Correct inhaler technique is of utmost importance in the optimal delivery of therapeutics utilized for respiratory illnesses. Previous research suggests that the ability of both patients and providers to correctly use these inhalers is sub-optimal and is associated with poorer patient outcomes. Further education about inhaler types and technique as part of residency education could serve to correct these trends. Methods Family medicine residents were taught correct inhaler technique with an inhaler training device (In-Check TM DIAL G16) using a didactic lecture with hands-on teaching exercise utilizing pharmacy interprofessional teaching. We assessed pre- and post-intervention comfort and knowledge of correct inhaler technique. Results Twenty of twenty-seven eligible family medicine residents attended an interdisciplinary workshop with clinical pharmacists with the purpose of improving inhaler technique comfort level and knowledge. A pre- and post-knowledge test and comfort questionnaire were provided to those participating. Comfort levels with prescribing different inhaler types increased after the intervention and knowledge of different inhalers improved. Conclusion Use of an inhaler training device coupled with an interdisciplinary lecture format improved provider knowledge of correct inhaler technique and comfort with prescribing inhalers.
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL
Othman, Tamer , Roloff, Gregory W. , Miller, Katharine, Zhang, Amy , Sutherland, Katherine C. , Faramand, Rawan , Hill, LaQuisa C. , Jeyakumar, Nikeshan , Ladha, Abdullah , Kopmar, Noam E., Tsai, Stephanie B., O'CONNOR, TIMOTHY E., Solh, Melhem , Guzowski, Caitlin, Tan, Virginia, Malik, Shahbaz A., Mathews, John, Shaughnessy, Paul , Mountjoy, Luke, Schwartz, Marc S., Connor, Matthew P. , Vasu, Sumithira, Kumaran, Muthu, Hoeg, Rasmus T., Tracy, Sean , Yaghmour, George , Pullarkat, Vinod , Muffly, Lori , Aldoss, Ibrahim, Jeyakumar, Nikeshan , Ladha, Abdullah , Sasine, Joshua , Lin, Chenyu , Hilal, Talal , Majhail, Navneet S , Dykes, Kaitlyn C , Logan, Aaron C , Connor, Matthew , Cassaday, Ryan D , Leonard, Jessica T , Shah, Bijal , Frey, Noelle V , Muffly, Lori , Hill, LaQuisa C , Faramand, Rawan , Sutherland, Katherine , Roloff, Gregory W , Othman, Tamer , Zhang, Amy , Muhsen, Ibrahim N. , Sasine, Joshua , Lin, Chenyu , Kopmar, Noam E. , Tsai, Stephanie, Hilal, Talal , Majhail, Navneet S. , Battiwalla, Minoo , Malik, Shahbaz A. , Mountjoy, Luke , Dykes, Kaitlyn C. , Wang, Jiasheng , Vasu, Sumithira , Hoeg, Rasmus T. , Yalniz, Fevzi , Cassaday, Ryan D. , Shah, Bijal , Frey, Noelle V. , Aldoss, Ibrahim

Mayo Clinic

Blood Advances | June 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020707 | PMID 42349018 Get It

Brexucabtagene-autoleucel (brexu-cel) produces high rates of measurable residual disease-negative (MRD-) complete response (CR) in adults with Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL); however, subsequent relapses remain frequent. It is unclear whether maintenance with tyrosine kinase inhibitors (TKIs) can enhance remission durability. We evaluated outcomes among adults with relapsed/refractory Ph+ ALL who received commercial brexu-cel and achieved MRD- CR across 19 U.S. institutions. Considering TKI maintenance as a time-varying covariate, we analyzed outcomes based on receipt of subsequent TKI maintenance versus no maintenance. Patients receiving consolidative transplantation or non-TKI maintenance were excluded. Fifty-one patients were included: 20 received TKI maintenance and 31 received no maintenance. The use of TKI maintenance was associated with a significantly lower 1-year cumulative incidence of relapse (HR 0.12; 95% CI, 0.02-0.88; p=0.037) which translated into improved progression-free survival (PFS, HR 0.19; 95% CI, 0.04-0.85; p=0.029) and a trend towards improved overall survival (OS, HR 0.34; 95% CI, 0.07-1.62; p=0.18). There was no difference in non-relapse mortality (NRM, HR 0.83; 95% CI, 0.12-5.87; p=0.85). This real-world analysis supports the administration of TKI maintenance in Ph+ ALL following achievement of MRD- CR with brexu-cel as a strategy to improve PFS following chimeric antigen receptor T cell therapy.
Menopause and Its Implications for Stroke in Women
Thurston, Rebecca C. , Spicuzza, Jocelyn M. Delgado , Schroeder, Rachel A. , Mak, Elijah , Miller, Eliza C. , Kantarci, Kajal, Spicuzza, Jocelyn M , Mak, Elijah , Kantarci, Kejal

Mayo Clinic

Stroke | June 24, 2026 | Volume: 57 | Issue: 8 | Pages: 2531-2541

10.1161/strokeaha.126.052889 | PMID 42339545 Get It

Stroke is the third leading cause of death in women and a major driver of disability. Menopause is a universal transition for midlife women, which is accompanied by menstrual cycle changes, hormonal fluctuations, and, for many women, the occurrence of menopausal symptoms. An accumulating body of research underscores the importance of menopause and its features to stroke risk in women, including the type and timing of menopause, endogenous hormone profiles, and menopausal symptoms, including vasomotor symptoms and sleep problems. In addition, menopausal hormone therapy, a leading approach to managing menopausal symptoms, has implications for stroke risk, which varies depending on the menopausal hormone therapy formulation, route of delivery, and the age and health of the recipient, with transdermal menopausal hormone therapy formulations administered to younger midlife women showing a more favorable profile. This review summarizes the data linking menopause and stroke, and offers suggestions to inform clinical decision-making. Knowledge gaps and directions for future research are highlighted.
Real-World Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Treatment Delivery, Immune Reconstitution, and Cardiac Monitoring During High-Dose IL-2
Aboelatta, Mohamed A. , Zarka, Jabra , Tchatchua, Nika , Aboelatta, Noureldin A., Johnson, Jeffrey , Jakub, James W. , Desroches, Justin , Wilson-Miller, Justine, Tabiim, Anthony Jagri , Behl, Deepti , Montane, Heather N. , Kottschade, Lisa A. , Dimou, Anastasios , Block, M. , Heath, Elisabeth I. , Doonan, Bently, Seetharam, ­Mahesh , Molina, Julian R. , Charnin, Jonathan E. , Gill, Paula, Lin, Yi, Baral, Binav , Markovic, Svetomir N., Dudek, Arkadiusz Z. , Johnson, Jeffrey E , Tabiim, Anthony , Jakub, James W , Dimou, Anastasios , Montane, Heather N , Dudek, Arkadiusz Z , Zarka, Jabra G , Tchatchua, Nika , Wilson-Miller, Justine L., Doonan, Bently P. , Markovic, Svetomir N.

Mayo Clinic

Current Oncology | June 24, 2026 | Volume: 33 | Issue: 7 | Pages: 379

10.3390/curroncol33070379 | PMID 42505181 Get It

Background/Objectives: Tumor-infiltrating lymphocyte (TIL) therapy is an important option for patients with metastatic melanoma progressing after standard systemic therapy, but real-world data on treatment delivery, toxicity monitoring, and immune recovery remain limited. We evaluated clinical outcomes, treatment tolerance, immune reconstitution, and cardiac biomarker dynamics across three Mayo Clinic sites. Methods: We retrospectively analyzed adults with metastatic melanoma who received lymphodepleting chemotherapy followed by TIL infusion and high-dose interleukin-2 (IL-2) between April 2024 and December 2025. Clinical outcomes, treatment delivery, and adverse events were assessed. Longitudinal immune monitoring included CD4 and CD8 T-cell counts, CD4:CD8 ratio, and immunoglobulin G (IgG) at baseline and follow-up. In a prespecified cardiac sub-cohort, high-sensitivity troponin (hs-Tn) was measured during IL-2 administration to evaluate associations with cardiac events and IL-2 interruption. Results: Thirty-six patients underwent TIL infusion. The objective response rate was 50.0%, including complete responses in 13.9%, and the disease control rate was 72.2%. Median progression-free survival was 3.61 months, and median overall survival was 12.94 months. M1d disease was associated with inferior overall survival on univariable analysis (HR 6.55, 95% CI 2.03–21.17; p = 0.002), with attenuation after multivariable adjustment. Receipt of ≥3 IL-2 doses was associated with longer overall survival on univariable analysis (HR 0.20, 95% CI 0.06–0.64; p = 0.007), but this association also attenuated after adjustment. Longitudinal immune monitoring demonstrated persistent CD4 lymphopenia through 6 months, sustained inversion of the CD4:CD8 ratio, and declining IgG at months 3 and 6. In the cardiac sub-cohort (24 patients; 87 IL-2 doses), post-dose hs-Tn ≥15 ng/L was associated with clinically significant cardiac events (OR 9.6, 95% CI 1.5–60.6; p = 0.016) and IL-2 interruption (OR 3.4, 95% CI 1.1–10.7; p = 0.036). For cardiac events, hs-Tn ≥15 ng/L had 100% sensitivity and 100% negative predictive value. Conclusions: In routine practice, TIL therapy was feasible and active in metastatic melanoma. M1d disease identified a subgroup with poor survival, peri-dose hs-Tn showed promise as a tool to support safer IL-2 delivery, and prolonged CD4 suppression with IgG decline suggests that recovery after TIL therapy extends beyond initial hematologic reconstitution. These findings support prospective validation of biomarker-guided IL-2 monitoring and extended post-treatment immune surveillance.